Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Transplantation

Graft-versus-host disease (GvHD)

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

TRAIL-overexpressing T cells could be useful for both treating GvHD and improving antitumor immunity following a hematopoietic stem cell transplant (HSCT). Mouse and human T cells were engineered to overexpress TRAIL, which is known to mediate graft-versus-tumor effects after HSCT. In mice receiving allogeneic HSCT and grafted with murine lymphoma cells, adoptive transfer of the TRAIL-overexpressing T cells resulted in 100% survival at 100 days, whereas mice receiving T cells without overexpression died from GvHD and lymphoma. In cell lines and samples from patients who have chronic lymphocytic leukemia (CLL), the human, TRAIL-overexpressing T cells showed more potent killing of both CLL and alloreactive T cells than did T cells with normal TRAIL expression. Next steps include developing a clinical trial to evaluate use of TRAIL-overexpressing T cells in patients whose disease has relapsed after an allogeneic HSCT.

SciBX 6(22); doi:10.1038/scibx.2013.554
Published online June 6, 2013

Unpatented; licensing status not applicable

Ghosh, A. et al. J. Clin. Invest.; published online May 15, 2013;
doi:10.1172/JCI66301
Contact: Arnab Ghosh, Memorial Sloan-Kettering Cancer Center,
New York, N.Y.
e-mail:
ghosha1@mskcc.org